NASDAQ · STOCK
CVS Health
$104.42
52W $61.19 – $110.68
51/100
$133.25B
45.2
0.60
Is CVS Bullish or Bearish?
Mixed.
Innellis AI committee rates CVS Health (CVS) Watch with a composite score of 51/100
, based on 7 analysts with 71% agreement.
Last updated July 31, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +9.17 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -10.83 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Technical Analyst sees a compelling case — price structure making higher highs and higher lows. Risk Analyst remains cautious — current ratio of 0.84 is tight -- limited short-term liquidity cushion. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Price-to-book of 1.3x is a discount to asset value — Value
- Dividend yield of 2.5% pays you to wait — Value
- 4 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- P/E of 45.8 is expensive by classic value standards — Value
- ROE of only 3.9% -- cheap may mean cheap for a reason — Value
- EPS declining -46.0% YoY despite any revenue growth — Growth
- MACD histogram negative -- bearish momentum — Technical
- Current ratio of 0.84 is tight -- limited short-term liquidity cushion — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of July 31, 2026
Overall Committee Score
51/100
Agreement
71%
Analysts
7
Conviction
Moderate
Sector Rank
Top 82%
of 93 Healthcare peers
Value Analyst
neutral
43
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ Price-to-book of 1.3x is a discount to asset value
− P/E of 45.8 is expensive by classic value standards
Growth Analyst
neutral
56
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ 4 consecutive earnings beats -- consistent execution
− EPS declining -46.0% YoY despite any revenue growth
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst
bearish
35
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Current ratio of 0.84 is tight -- limited short-term liquidity cushion
Macro Analyst
neutral
58
/ 100 · Moderate confidence
Macro backdrop is mixed or neutral -- not a strong tailwind or headwind either way
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2744.14)
Investment Thesis Evolution
Committee score moved marginally from 51.9 to 50.8.
- Conviction changed from contested to moderate.
- Committee agreement increased notably from 57% to 71%.
- New bearish signals: 3 appeared.
- New bullish signals: 1 appeared.
- Bearish pressure eased: 3 signal(s) disappeared.
- Analyst(s) changed stance: Macro Analyst.
Analyst-level changes:
- Macro Analyst: stance bullish->neutral; score 65->58 (-8); +1 bullish signal(s).
- Portfolio Manager: +2 bearish signal(s).
- Value Analyst: +1 bearish signal(s).
Comparing 2026-07-30 to 2026-07-31 (1 day apart).
Technical Analysis
RSI (14)
39.8
Neutral
MACD Histogram
-0.678
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Support
$100.27
Resistance
$104.62
Bollinger %B
0.30
Inside Bands
Price vs Moving Averages
EMA 9
$106.35
Below
EMA 21
$105.57
Below
EMA 50
$100.96
Above
EMA 200
$86.63
Above
Fundamental Analysis
Valuation
66
Growth
94
Profitability
0
Financial Health
40
Cash Flow
37
Valuation
P/E Ratio
45.2×
P/B Ratio
1.72×
PEG Ratio
-1.00
Dividend Yield
0.03%
52W High
$110.68
52W Low
$61.19
Quality & Growth
ROE
2.4%
ROA
0.7%
Gross Margin
13.9%
Operating Margin
1.5%
Revenue Growth YoY
—
Debt / Equity
1.01
AI Fundamental Assessment
P/E ratio of 45.2 (rich relative to a 15-40x range); Price-to-book of 1.7x; PEG ratio of -1.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.0%; Return on assets of 0.0%; Net margin of 0.0%; Gross margin of 0.1%; Current ratio of 0.87 (tight short-term liquidity); Debt-to-equity of 1.01; Free cash flow margin of 0.7% (thin cash generation); Free cash flow per share is positive (5.81); Most recent quarter beat estimates by 15.8%; 4 consecutive earnings beats; EPS growth accelerating (-31.9% -> +135.8% QoQ); Analyst estimates rising over recent quarters
Get the Full CVS Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →